These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1782640)

  • 21. [The antiandrogen treatment of patients with prostatic cancer and bone metastases].
    Matveev BP; Bukharkin BV; Zhumagazin ZhD
    Urol Nefrol (Mosk); 1993; (1):10-4. PubMed ID: 7941115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Total androgen ablation: Canadian experience.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Urol Clin North Am; 1991 Feb; 18(1):75-82. PubMed ID: 1992574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R; Pahalajani G; Agarwal A; Zippe C
    Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
    Hucher M; de Gery A; Bertagna C
    Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
    [No Abstract]   [Full Text] [Related]  

  • 28. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
    Labrie F; Dupont A; Cusan L; Gomez JL; Diamond P
    Clin Invest Med; 1993 Dec; 16(6):493-8. PubMed ID: 8013154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group.
    Semin Urol; 1990 Aug; 8(3):159-65. PubMed ID: 2204980
    [No Abstract]   [Full Text] [Related]  

  • 33. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
    Navratil H
    Prog Clin Biol Res; 1987; 243A():401-10. PubMed ID: 3116551
    [No Abstract]   [Full Text] [Related]  

  • 34. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ocular toxicity of Anandron in patients treated for prostatic cancer.
    Harnois C; Malenfant M; Dupont A; Labrie F
    Br J Ophthalmol; 1986 Jun; 70(6):471-3. PubMed ID: 3718913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Complete androgen blockage in the treatment of metastatic prostate cancer].
    Matzkin H; Braf Z
    Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104
    [No Abstract]   [Full Text] [Related]  

  • 37. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.
    González-Barcena D; Schally AV; Vadillo-Buenfil M; Cortez-Morales A; Hernández L V; Cardenas-Cornejo I; Comaru-Schally AM
    Prostate; 2003 Aug; 56(3):183-91. PubMed ID: 12772187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
    Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
    Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Fatal fulminant hepatitis induced by nilutamide (Anandron)].
    Pescatore P; Hammel P; Durand F; Bertheau P; Bernuau J; Huc D; Gerbal JL; Degott C; Benhamou JP
    Gastroenterol Clin Biol; 1993; 17(6-7):499-501. PubMed ID: 8243938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group.
    Dijkman GA; Fernandez del Moral P; Debruyne FM; Janknegt RA
    Eur Urol; 1995; 27(3):196-201. PubMed ID: 7601182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.